Clinicians can distinguish cannabis hyperemesis from diabetic gastroparesis using age, sex, and diabetes duration

In people with type 1 diabetes, older age, longer diabetes duration, female sex, lower A1C, and diabetic neuropathy favor a diagnosis of gastroparesis over cannabis hyperemesis syndrome.

Akturk, Halis Kaan et al.·Clinical diabetes : a publication of the American Diabetes Association·2025·Preliminary EvidenceCross-Sectional
RTHC-05889Cross SectionalPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

The study identified clinical features that help differentiate diabetic gastroparesis (DG) from cannabinoid hyperemesis syndrome (CHS) in people with type 1 diabetes, two conditions with substantially overlapping presentations of nausea, vomiting, and abdominal pain. Older age, longer diabetes duration, female sex, lower A1C, and presence of diabetic neuropathy were indicators favoring DG over CHS.

Key Numbers

Differentiating factors: older age, longer diabetes duration, female sex, lower A1C, and diabetic neuropathy favor gastroparesis over CHS

How They Did This

Clinical comparison study of people with type 1 diabetes presenting with symptoms consistent with either diabetic gastroparesis or cannabis hyperemesis syndrome. Specific sample size and study design details limited in the brief report format.

Why This Research Matters

Cannabis hyperemesis and diabetic gastroparesis present nearly identically, and misdiagnosis in either direction leads to inappropriate treatment. As cannabis use increases among people with diabetes, clinicians need practical tools to tell these conditions apart.

The Bigger Picture

Cannabis hyperemesis syndrome has become increasingly recognized as cannabis use rises, but its overlap with common gastrointestinal conditions creates diagnostic challenges. This is especially relevant in populations with pre-existing GI conditions like diabetic gastroparesis.

What This Study Doesn't Tell Us

Brief clinical report with limited sample size details. Retrospective identification of differentiating factors may not fully capture the complexity of clinical presentations. Does not address cases where both conditions may co-occur.

Questions This Raises

  • ?How often is CHS misdiagnosed as diabetic gastroparesis in clinical practice?
  • ?Could a validated screening tool incorporating these clinical features improve diagnostic accuracy?

Trust & Context

Key Stat:
Older age and neuropathy favor gastroparesis; younger age favors CHS
Evidence Grade:
Brief clinical report provides useful practical guidance but lacks detailed methodology and sample size information, limiting confidence in the specificity of differentiating features.
Study Age:
2025 publication
Original Title:
Differentiating Diabetic Gastroparesis and Cannabis Hyperemesis Syndrome in People With Type 1 Diabetes.
Published In:
Clinical diabetes : a publication of the American Diabetes Association, 43(3), 416-419 (2025)
Database ID:
RTHC-05889

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

Why is it hard to tell these conditions apart?

Both cannabinoid hyperemesis syndrome and diabetic gastroparesis cause recurrent nausea, vomiting, and abdominal pain. In a person with type 1 diabetes who uses cannabis, either or both conditions could explain the symptoms.

What clues point toward cannabis hyperemesis instead of gastroparesis?

Younger age, shorter diabetes duration, male sex, higher A1C, and absence of diabetic neuropathy favor a CHS diagnosis, along with a history of prolonged cannabis use and symptom relief with hot showers.

Read More on RethinkTHC

Cite This Study

RTHC-05889·https://rethinkthc.com/research/RTHC-05889

APA

Akturk, Halis Kaan; Mason, Emma; Snell-Bergeon, Janet; Shah, Viral N; Karakus, Kagan Ege. (2025). Differentiating Diabetic Gastroparesis and Cannabis Hyperemesis Syndrome in People With Type 1 Diabetes.. Clinical diabetes : a publication of the American Diabetes Association, 43(3), 416-419. https://doi.org/10.2337/cd24-0096

MLA

Akturk, Halis Kaan, et al. "Differentiating Diabetic Gastroparesis and Cannabis Hyperemesis Syndrome in People With Type 1 Diabetes.." Clinical diabetes : a publication of the American Diabetes Association, 2025. https://doi.org/10.2337/cd24-0096

RethinkTHC

RethinkTHC Research Database. "Differentiating Diabetic Gastroparesis and Cannabis Hypereme..." RTHC-05889. Retrieved from https://rethinkthc.com/research/akturk-2025-differentiating-diabetic-gastroparesis-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.